Alex Zukiwski, Ph.D. Oncology clinical development executive

Dr. Zukiwski has held many leadership roles in global oncology drug development and has supported the clinical evaluation, regulatory affairs, and registration of many successful therapeutic agents, including Taxotere, Xeloda, Procrit/ Eprex, Velcade, Yondelis, and Doxil in companies such as CASI Pharmaceuticals, Arno Therapeutics, MedImmune, Johnson and Johnson, Centocor R&D and Ortho Biotech. Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. He has been a director and advisor to various pharmaceutical companies. Dr. Zukiwski holds BSc in Pharmacy and medical degree from the University of Alberta and the University of Calgary. He conducted his post- graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas M.D. Anderson Cancer Center.